Background: To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell infusion [high-dose chemotherapy (HD-CT arm)] to four cycles of standard cisplatin, etoposide, and bleomycin (BEP) in patients with poor-prognosis germ-cell cancer (GCC).
introduction
The development of effective chemotherapy such as cisplatin, etoposidel, and bleomycin (BEP) has dramatically improved the prognosis of patients with metastatic nonseminomatous germ-cell cancer (GCC). However, patients with poor prognosis according to the International Germ Cell Cancer Collaborative Group criteria (IGCCCG) [1] only achieve longterm survival rates of 50%-60%.
In order to improve these results, the German Testicular Cancer Study Group (GTCSG) developed a dose intensification approach, consisting of one cycle of cisplatin, etoposide, and ifosfamide (VIP) with stem-cell mobilization followed by three to four sequential high-dose cisplatin, etoposide, and ifosfamide (HD-VIP) cycles each with granulocyte colony-stimulating factor (G-CSF) and peripheral blood stem-cell transfusion at 21-day intervals, in order to achieve an early dose intensification [2] [3] [4] . The dose levels of etoposide 1500 mg/m 2 and ifosfamide 12 g/m 2 with standard dose cisplatin per cycle was recommended [3] and chosen for this trial protocol.
The aim of the present study was (i) to compare the efficacy of one cycle of standard dose VIP plus three cycles of HD-VIP followed by stem-cell infusion to four cycles of standard BEP in previously untreated patients with poor-prognosis GCC and (ii) to compare the toxicity of these two treatments.
The study was conducted by the European Organization for Research and Treatment of Cancer (EORTC) in collaboration with the GTCSG and the Spanish Grupo Germinal.
patients and methods inclusion criteria and patient characteristics
Adult male patients aged 15-50 years with previously untreated metastatic poor-prognosis nonseminoma GCC according to IGCCCG classification [1] of either testicular or extragonadal origin were eligible for randomization regardless of the performance status and clinical presentation. However, in the case of massive pulmonary disease, it was allowed to administer 2-3 days of cisplatin and etoposide and then postpone randomization 2-3 weeks.
Diagnosis was established by either histological examination or a characteristic clinical presentation with an elevated level of serum human chorionic gonadotropin (HCG) and/or a-fetoprotein (AFP) corresponding to the IGCCCG poor prognostic group.
All patients gave written informed consent according to the International Conference on Harmonisation/WHO Good Clinical Practice standards and national regulations. The protocol was reviewed and approved by the Ethics Committee in each institution. The trial was conducted in accordance with the Declaration of Helsinki. This trial is registered with ClinicalTrials.gov as NCT00003941.
study design and treatment
Patients were randomly assigned to receive either BEP regimen or VIP followed by high-dose chemotherapy with peripheral stem-cell support [high-dose chemotherapy (HD-CT arm)] (Table 1) . Peripheral stem cells were reinfused on day 7, 48 h after the last infusion of chemotherapy. All patients received G-CSF during the recovery period. The second and third cycle of high-dose therapy was administered if hematologic toxicity was less than grade 1, nonhematologic toxicity less than grade 2, and performance status (World Health Organization) less than grade 2. Patients who did not fulfill the above criteria would have their treatment postponed for up to 2 weeks and, if still unresolved, would go off study treatment.
Details of supportive care after HD-CT were determined according to the preference of the individual participating centers.
assessment of safety and treatment response
The pretreatment evaluation included physical examination, pulmonary function tests, audiometry, measurement of serum tumor markers [lactate dehydrogenase (LDH), AFP, and HCG], hematology and biochemistry panel, and computed tomography scan of cerebrum, chest, abdomen, and pelvis. For both groups, assessments during treatment included a physical examination, a comprehensive serum-screening chemistry panel, and measurements for AFP, HCG, and serum LDH. HD-CT was routinely administered on an inpatient basis.
After completion of the allocated chemotherapy, patients with normal levels of tumor markers and no clinical or radiological evidence of residual masses were classified as complete responders and were monitored without further therapy. Patients in whom markers normalized, but who showed evidence of residual tumor mass, underwent debulking surgery. The protocol advised complete macroscopic resection of all tumor remnants. These patients were classified as complete responders if the histological examination showed no viable cancer cells. If viable malignancy was found and it was considered that it had been resected completely, the patients were classified as having been rendered disease free by chemotherapy plus surgery and is referred to as 'no evidence of disease' in the table. Patients in whom the surgical resection of residual disease was incomplete, those who had continuing elevation of tumor markers, or those who had disease progression while receiving chemotherapy or within 2 months after the completion of chemotherapy were classified incomplete responders. Rising tumor markers or an increase in tumor volume (unless this was caused by mature teratoma that was completely resectable) was considered progression of disease. Incomplete responders and patients with disease progression during treatment are reported as 'treatment failure' in the table. Patients with residual masses who did not undergo debulking surgery were classified nonassessable for response and included in disease-free (progression-free) survival and survival analyses. Events in the failure-free survival (FFS) analysis were treatment failure, progression of disease during follow-up, and death due to any cause.
Patients were followed up every month during the first year, every 2 month the second year, then every 6 months for 3 years and yearly thereafter.
Toxicity was evaluated according to The National Cancer InstituteCommon Toxicity Criteria version 2.0.
statistical considerations
Patients were randomized in a 1 : 1 ratio between the BEP and HD-CT arms using a minimization algorithm [5] stratifying for center, mediastinal germcell tumor, and presence of nonpulmonary visceral metastases.
The primary end point was FFS. Response to treatment, overall survival, and toxicity were secondary end points.
The protocol was planned to detect a 15% difference in the 1-year FFS rate. To that aim, a total of 222 patients were to be recruited. However, recruitment was slow; therefore, the EORTC Executive Committee closed the trial in June 2007, with 137 patients randomized.
The primary comparison is by unstratified log-rank test [6] and according to intention to treat. Response rates were compared by chisquare test. Sensitivity analyses were conducted by (i) stratifying the analysis for the presence of nonpulmonary visceral metastases [6] and (ii) restricting the analysis to the eligible patients who started the allocated treatment ('per protocol'). Survival and FFS were estimated by the Kaplan-Meier method [7] .
To account for one interim analysis, statistical significance is claimed at the two-sided 0.049 level (O'Brien-Fleming alpha-spending function) [8] .
influence of marker half-life
The marker half-life for AFP and HCG was computed based on the values reported between day 7 of cycle 1 and day 1 of cycle 3 (or day 42 if only two cycles were given). Per protocol, this corresponded to values at day 21 of cycle 1 and of cycle 2, respectively, as in this study, marker values were only measured before each cycle. The log-transformed values were then regressed over time (ln(marker) = a + b · time) to obtain the estimated slope of the marker decline, separately for AFP (b = slope 2 AFP) and for HCG (b = slope 2 HCG). The half-life was calculated through the formula: T1/2 = 2ln(2)/slope. The marker decline was considered satisfactory, for AFP if T1/2 2 AFP was £7 days and for HCG if T1/2 2 HCG was £3.5 days [9] . Patients whose marker value normalized (value £ 10 IU/l) were classified as having a satisfactory decline for that marker.
Finally, patients were then classified as having overall a rapid decline if either both their marker declines were satisfactory or only one of their marker was elevated (>10 IU/l) at baseline and the decline for this marker was satisfactory. Heterogeneity of treatment effects across subgroups was assessed by log-rank test for heterogeneity [6] . The statistical power for this test is, however, low because of the small number of events and patients available for this analysis.
results
Between April 1999 and June 2007, 137 patients from 27 European oncology centers were included ( Figure 1 ). Two sites, with three patients each, were excluded due to poor data documentation. Of 131 patients included in this analysis, 11 were considered ineligible: four due to treatment before registration and seven did not fulfill the inclusion criteria (not poor prognosis, low renal function, conditioning with etoposide and cisplatin without reason). The baseline characteristics of the 131 patients are shown in Table 2 . The median follow-up is 4.4 years overall and is similar in the two arms. Overall, 95.7% of the patients were followed for >1 year.
All 66 patients who were randomly assigned to BEP started treatment. Of 65 patients allocated to HD-CT, 62 (95.4%) received that treatment: one ineligible patient was not treated, one refused treatment, and one refused HD-CT and received BEP. In the BEP arm, 93.8% of patients received four cycles of scheduled treatment compared with 75.4% in the HD-CT arm and as expected the main reason for this was toxicity.
Toxicity was more severe for patients treated on the HD-CT arm (Tables 3 and 4) . Seven (5%) of 131 patients died during treatment. Three died of toxicity (Table 5) : two who were assigned to the HD-CT arm died of sepsis (one after his first cycle of standard dose VIP) and one on the BEP arm who died of cardiac failure. The other patients died of lung embolus (one) or malignant disease (three).
The dose intensity in the BEP arm was 97.7%, while the dose intensity in the HD-CT arm was 89.3%. One or more cycles were postponed in 25% of the patients in the BEP arm compared with 66% in the HD-CT arm. This was mainly due to patient wish or infrastructure problems and not toxicity.
response and survival status by treatment arm
There was no improvement in complete response rate for patients treated on the HD-CT arm compared with patients treated on the BEP arm [(intention to treat) 44.6% versus 33.3% (P = 0.18)]. There was overall no difference in FFS between the two treatment arms (log-rank P = 0.057; Figure 2 ). The 1-year FFS rate was 48% [95% confidence interval (CI) 35.5%-59.5%] after BEP and 66.1% (95% CI 53.1%-76.2%) after HD-CT with a difference of 18.1% [standard deviation (SD) = 7.3%] (P = 0.035). The 2-year FFS rate was 44.8% (95% CI 32.5%-56.4%) after BEP and 58.2% after HD-CT (95% CI 48.0-71.9). The difference of 16.3% (SD 7.5%) in the 2-year FFS rates was not statistically significant (P = 0.060).
Overall survival did not differ between the two groups (log-rank P > 0.1) (Figure 2 ).
On BEP, 83% of patients survived 1 year (95% CI 71.3%-90.2%) and 65.5% (95% CI 52.4%-75.8%) survived 2 years. For the HD-CT arm, the 1-and 2-year survival rates were 86.1% (95% CI 74.9%-92.5%) and 72.9% (95% CI 60.0%-82.3%), respectively.
The assessment of the prognostic value of marker half-life was conducted in the subset of 116 patients with at least two treatment cycles for whom the marker half-life could be calculated (62 BEP and 54 HD-CT). 
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Marker decline was not prognostic for FFS or overall survival (P > 0.1). However, there was a borderline significant interaction between treatment and marker decline for FFS (P = 0.05) and a suggestion for a greater benefit from VIP in patients with satisfactory marker decline. Data are shown in Table 6 .
discussion
The primary trial end point in the present study was FFS, which was calculated as the time to treatment failure, later disease progression or death due to any cause. The hazard ratio for this end point was 0.62 (in favor of HD-VIP) with adjusted 95% CI from 0.38 to 1.02 and this did just not make the limits of statistical significance (P = 0.057 to compare with a = 0.049). At 1 year, the failure-free rates were 48% on BEP (95% CI 35.5-59.5) and 66.1% on HD-VIP (95% CI 53.1-76.2). There was no significant difference in overall survival. Several retrospective and phase II studies have been undertaken using HD-CT and with promising response rates [10, 11] . Einhorn et al. [12] have recently carried out a retrospective review of treatment results in 184 patients treated with HD-CT as second-line, third-line, or later therapy. The majority of patients had two cycles of HD-CT. A prognostic scoring algorithm was developed and patients were divided into a low-, intermediate-, and high-risk group with a 5-year survival 80%, 60%, and 40%, respectively [12] . Due to the documented activity of HD-CT with blood stemcell support in patients with relapsed disease, it was a logical step to use this approach as a first-line treatment in poorprognosis patients with a high risk of relapse. However, no prospective randomized study has so far been able to show a benefit of HD-CT compared with standard BEP. Likewise, the present study showed no significant improvement in complete remission or overall survival in patients treated with sequential HD-VIP compared with BEP. There was a large difference in 1-year FFS rates of patients treated with HD-VIP compared with BEP; however, this difference in 1-year rates did not result in a statistically significant difference of the FFS curves (P = 0.057). This lack of statistical significance is likely due to the fact that the study was stopped prematurely after only 137 of 222 patients planned in the trial had been entered. Of note, the observed difference in 1-year FFS rates (18.1% 6 SD 7.3%) is commensurate with the 15% difference in 1-year rates that the original protocol was planned to detect.
When comparing the results achieved in the present study with previous data from a matched pair analysis comparing HD-CT with standard dose BEP/VIP [4] , they appear remarkably similar. In the matched paired analysis, sequential HD-VIP achieved a 2-year progression free survival (PFS) of 75% versus 59% for standard BEP and a 2-year overall survival of 82% versus 71% for BEP. The corresponding results in this randomized study are 73% versus 65.5% for overall survival and 61.1% versus 44.8% for PFS at 2 years. This indicates that there could be a difference of 10%-15% between HD-CT and BEP, but this could not be statistically confirmed in the present study due to the small number of patients included (only about 60% of planned number of patients).
The toxicity of the HD-VIP arm was as anticipated from the previous two phase I/II studies of the GTCSG [2, 3] . More than 80% of patients only had one stem-cell harvest carried out and the achieved relative dose intensity of HD-VIP was 90% for all three drugs included in the regimen. As expected, there was original article Annals of Oncology significantly more grade 4 hematological toxicity with HD-VIP, but only one patient died of septic complications. There were a total of seven fatal serious adverse events (SAEs) in the present study that was possibly or probably related to treatment (three on BEP and four on HD-VIP). Three of the deaths due to SAE on HD-VIP occurred during the first cycle (of standard dose VIP). The files of two patients were reviewed by the Study Coordinator, who considered them as early deaths due to malignant disease. The analysis also indicated an increased rate of severe toxicity on HD-VIP for the items related to febrile neutropenia, infection, and gastrointestinal toxicity (nausea, vomiting, and stomatitis/mucositis). In comparison to the US intergroup study results [13] , the number of patients who obtained complete response in the present study (43% HD-VIP versus 30% BEP) was lower than the number obtained in the study by Motzer et al. (56% HD-CT versus 55% BEP). The reason for this difference might be the high number of nonassesable patients in the present study and the inclusion of intermediate-risk patients in the American study. In our protocol, it was stated that all patients should be submitted to surgical removal of residual disease, but this was not achievable in around 30% of the cases. However, the 1-and 2-year survival rates in both studies are comparable, likewise is the FFS in the BEP arm. The FFS in the high-dose arm in the present study is much longer than in the study of Motzer et al. (82.4 versus 23.2 months) . In contrast to the study of Motzer et al. [13] , the majority of patients in the present study allocated to HD-CT did start this treatment, 83 (77%) versus 63 (97%) (present study). The number of patients who died during treatment is equal in the two studies.
The speed of decline of AFP and b-HCG seemed not to be prognostic for FFS or overall survival. The data suggested that patients with satisfactory marker decline might possibly benefit more from HD-VIP than the others, but this was a post hoc subgroup analysis and there was not enough statistical power to test for an interaction between speed of marker decline and treatment effect. The data are in contrast to the study by Motzer et al. [13] , who found that patients with slow serum tumor marker decline (AFP and/or b-HCG) during the first two cycles of chemotherapy had a shorter progression-free survival and overall survival compared with patients with satisfactory marker decline (P = 0.02 and P = 0.03, respectively). Among 67 patients with unsatisfactory marker decline, the 1-year durable complete response proportion was 61% for patients who received HD-CT versus 34% for patients receiving BEP alone (P = 0.03) [13] .
In conclusion, there is no clear evidence that high-dose chemotherapy plus autologous hematopoietic stem-cell support given as part of first-line therapy increase survival in patients with poor-prognosis GCC. Although this randomized trial indicates about 10% absolute improvement at 2 years with HD-VIP, it was not possible to demonstrate a statistical significance of this difference due to early study closure.
If not used in first-line therapy, HD-CT will still remain of importance at relapse. An international collaborative group is working on a definition of favorable or unfavorable prognostic criteria for relapsing patients and this could have a significant impact on the success of choosing patients for conventional or high-dose salvage chemotherapy in the future. To maintain the highest chance of cure, patients with a poor prognosis or relapsed disease should be transferred to a specialized center without any delay to benefit from optimal interdisciplinary management and supportive care [14] . In order to improve on the poor outcome for poor-risk GCC, further clarification of the role of HD-CT as well as new combinations of drugs should be investigated in well-designed clinical trials and this can only be achieved by close international collaboration. 
